Heart Transplant
44
10
13
15
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
6.8%
3 terminated out of 44 trials
83.3%
-3.2% vs benchmark
18%
8 trials in Phase 3/4
53%
8 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (44)
Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial
Belatacept in Heart Transplantation
Expanding the Pool in Orthotopic Heart Transplantation
Effect of Resistance Training in Patients on the Waiting List for Heart Transplant
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
SWITCH: Apixaban vs Vitamin K in HM3
Tocilizumab in Cardiac Transplantation
Registry for Longitudinal Evaluation of Heart Transplanted Patients
Randomized Trial of SGLT2i in Heart Transplant Recipients
Enhancing Heart Allograft Function With the OCS Heart System Trial
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
US National OCS Heart Perfusion (OHP) Registry
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
OCS DCD Heart + CAP Continued Follow-Up
Exercise aNd hEArt Transplant
Observational Study With Additional Procedures: Metabolomic and Ultrastructural Findings of Allograft in Heart Transplantation and Their Correlation With Graft Dysfunction.
Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
OCS Heart EXPAND + CAP Continued Follow-Up